However, among medications that are already widely used in patients with DN, only a few antidiabetic drugs, including renin angiotensin system (RAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists, have demonstrated a potential renal benefits [4–6]. Here, SLC5A2 is linked to liver dysplastic nodule.